NASDAQ:MDXG MiMedx Group (MDXG) Stock Forecast, Price & News $7.70 -0.08 (-1.03%) (As of 09/21/2023 ET) Add Compare Share Share Today's Range$7.57▼$7.7550-Day Range$6.71▼$8.1652-Week Range$2.43▼$8.60Volume388,370 shsAverage Volume686,714 shsMarket Capitalization$894.05 millionP/E RatioN/ADividend YieldN/APrice Target$12.50 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media MiMedx Group MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside62.3% Upside$12.50 Price TargetShort InterestHealthy2.96% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings Growth625.00%From $0.04 to $0.29 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.16 out of 5 starsMedical Sector464th out of 961 stocksSurgical & Medical Instruments Industry49th out of 95 stocks 3.5 Analyst's Opinion Consensus RatingMiMedx Group has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $12.50, MiMedx Group has a forecasted upside of 62.3% from its current price of $7.70.Amount of Analyst CoverageMiMedx Group has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.96% of the float of MiMedx Group has been sold short.Short Interest Ratio / Days to CoverMiMedx Group has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in MiMedx Group has recently increased by 3.16%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldMiMedx Group does not currently pay a dividend.Dividend GrowthMiMedx Group does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MDXG. Previous Next 0.6 News and Social Media Coverage Search InterestOnly 4 people have searched for MDXG on MarketBeat in the last 30 days. This is a decrease of -43% compared to the previous 30 days.MarketBeat Follows7 people have added MiMedx Group to their MarketBeat watchlist in the last 30 days. This is an increase of 133% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, MiMedx Group insiders have not sold or bought any company stock.Percentage Held by Insiders19.90% of the stock of MiMedx Group is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions43.85% of the stock of MiMedx Group is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for MiMedx Group are expected to grow by 625.00% in the coming year, from $0.04 to $0.29 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MiMedx Group is -45.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MiMedx Group is -45.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About MiMedx Group (NASDAQ:MDXG) StockMiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a semi-permeable protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications; and AMNIOBURN a semi-permeable protective barrier allograft used in the treatment of partial-thickness and full-thickness burns, as well as lead product includes mdHACM, a micronized form of AMNIOFIX, supplied in powder form. The company's products have applications primarily in the areas of wound care, burn, surgical, and non-operative sports medicine sectors of healthcare. It also sells allografts for dental applications on an original equipment manufacturer basis. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was incorporated in 2011 and is headquartered in Marietta, Georgia.Read More MDXG Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MDXG Stock News HeadlinesAugust 31, 2023 | msn.comMimedx Group (MDXG) Price Target Increased by 19.14% to 12.30August 15, 2023 | finance.yahoo.comMediWound Announces Collaboration with MIMEDX on EscharEx® Phase III StudySeptember 21, 2023 | Behind the Markets (Ad)BREAKING: The truth about war with ChinaForeign Affairs reports, "China is Now in a Prewar Tempo of Political and Military Preparations." China has one goal: take control of Taiwan, and an invasion could happen any day. I've identified 5 investments I believe are in immediate danger. But you can get out of them now - before it's too late.August 10, 2023 | seekingalpha.comMiMedx Group, Inc. 2023 Q2 - Results - Earnings Call PresentationAugust 2, 2023 | finance.yahoo.comMDXG: Beat and a RaiseAugust 2, 2023 | finance.yahoo.comQ2 2023 MiMedx Group Inc Earnings CallAugust 2, 2023 | finanznachrichten.deMiMedx Group, Inc: MIMEDX Announces Second Quarter 2023 Operating and Financial ResultsAugust 2, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Their Buy Rating for MiMedx Group (MDXG)September 21, 2023 | Behind the Markets (Ad)BREAKING: The truth about war with ChinaForeign Affairs reports, "China is Now in a Prewar Tempo of Political and Military Preparations." China has one goal: take control of Taiwan, and an invasion could happen any day. I've identified 5 investments I believe are in immediate danger. But you can get out of them now - before it's too late.August 1, 2023 | finance.yahoo.comMIMEDX Announces Second Quarter 2023 Operating and Financial ResultsJuly 25, 2023 | seekingalpha.comMiMedx Stock: Strategic Realignment Can Unlock ValueJuly 18, 2023 | finance.yahoo.comMIMEDX to Host Second Quarter 2023 Operating and Financial Results Conference Call on August 1July 11, 2023 | finance.yahoo.comMIMEDX Announces Favorable Ruling in Putative Securities Class Action CaseJuly 6, 2023 | msn.comMimedx Group (MDXG) Price Target Decreased by 11.76% to 9.56July 5, 2023 | finanznachrichten.deMiMedx Group, Inc: MIMEDX Appoints Doug Rice as Chief Financial OfficerJuly 5, 2023 | finance.yahoo.comMIMEDX Appoints Doug Rice as Chief Financial OfficerJune 28, 2023 | msn.comMiMedx Group climbs 4%, reports CEO buying $640K stockJune 22, 2023 | finance.yahoo.comMDXG: KOA Program DiscontinuedJune 22, 2023 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: MiMedx Group (MDXG), Arbutus Biopharma (ABUS)June 21, 2023 | markets.businessinsider.comMiMedx Targets Profitability with Strategic Realignment, Suspends Knee Osteoarthritis Program ActivitiesJune 20, 2023 | marketwatch.comMiMedx Group Plans Strategic Realignment to Focus on Wound and Surgical BusinessJune 20, 2023 | finance.yahoo.comMIMEDX Announces Strategic Realignment: Increases Focus on Wound & Surgical Business, Expected to Significantly Improve ProfitabilityJune 20, 2023 | msn.comMiMedx pulls plug on knee osteoarthritis, regenerative medicine programsJune 20, 2023 | finance.yahoo.comMIMEDX Announces Strategic Realignment: Increases Focus on Wound & Surgical Business, Expected to Significantly Improve ProfitabilityMay 25, 2023 | finance.yahoo.comBreakeven On The Horizon For MiMedx Group, Inc. (NASDAQ:MDXG)May 18, 2023 | benzinga.comMiMedx Group President Trades Company's StockMay 6, 2023 | seekingalpha.comMiMedx's Post-Q1 2023 Surge Could Result In Profit-TakingSee More Headlines Receive MDXG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MiMedx Group and its competitors with MarketBeat's FREE daily newsletter. Email Address MDXG Company Calendar Last Earnings11/02/2021Today9/21/2023Next Earnings (Estimated)11/01/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MDXG CUSIPN/A CIK1376339 Webwww.mimedx.com Phone(770) 651-9100Fax678-384-6741Employees867Year FoundedN/APrice Target and Rating Average Stock Price Forecast$12.50 High Stock Price Forecast$14.00 Low Stock Price Forecast$11.00 Forecasted Upside/Downside+61.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.17) Trailing P/E RatioN/A Forward P/E Ratio193.25 P/E GrowthN/ANet Income$-30,200,000.00 Net Margins-6.58% Pretax Margin-4.26% Return on EquityN/A Return on Assets-11.27% Debt Debt-to-Equity RatioN/A Current Ratio3.18 Quick Ratio2.80 Sales & Book Value Annual Sales$267.84 million Price / Sales3.35 Cash FlowN/A Price / Cash FlowN/A Book Value($0.16) per share Price / Book-48.31Miscellaneous Outstanding Shares116,110,000Free Float93,003,000Market Cap$897.53 million OptionableOptionable Beta1.61 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. William F. Hulse IV (Age 49)Gen. Counsel & Chief Admin. Officer Comp: $677.36kDr. Robert Benjamin Stein M.D. (Age 72)Ph.D., Pres of Regenerative Medicine & Biologics Innovation Comp: $639.28kMr. Joseph H. Capper (Age 59)CEO & Director Mr. Douglas C. Rice CPA (Age 57)Chief Financial Officer Mr. Scott M. Turner (Age 57)Sr. VP of Operations & Procurement Mr. William L. PhelanSr. VP & Chief Accounting OfficerMr. Matthew M. NotarianniHead of Investor RelationsMr. Mark P. Graves (Age 57)Sr. VP & Chief Compliance Officer Hilary DixonVP of Investor Relations & Corp. Strategic CommunicationsMs. Kate SurdezChief HR OfficerMore ExecutivesKey CompetitorsEmbectaNASDAQ:EMBCTreace Medical ConceptsNASDAQ:TMCISI-BONENASDAQ:SIBNBeauty HealthNASDAQ:SKINOrthoPediatricsNASDAQ:KIDSView All CompetitorsInsiders & InstitutionsCalifornia State Teachers Retirement SystemBought 6,294 shares on 8/21/2023Ownership: 0.097%Wells Fargo & Company MNBought 9,574 shares on 8/15/2023Ownership: 0.085%Lazard Asset Management LLCBought 2,349 shares on 8/15/2023Ownership: 0.025%Royal Bank of CanadaBought 5,515 shares on 8/15/2023Ownership: 0.010%Fairfield Bush & CO.Bought 7,652 shares on 8/15/2023Ownership: 0.007%View All Insider TransactionsView All Institutional Transactions MDXG Stock - Frequently Asked Questions Should I buy or sell MiMedx Group stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MiMedx Group in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MDXG shares. View MDXG analyst ratings or view top-rated stocks. What is MiMedx Group's stock price forecast for 2023? 2 brokerages have issued 1-year price targets for MiMedx Group's stock. Their MDXG share price forecasts range from $11.00 to $14.00. On average, they expect the company's share price to reach $12.50 in the next year. This suggests a possible upside of 61.7% from the stock's current price. View analysts price targets for MDXG or view top-rated stocks among Wall Street analysts. How have MDXG shares performed in 2023? MiMedx Group's stock was trading at $2.78 on January 1st, 2023. Since then, MDXG shares have increased by 178.1% and is now trading at $7.73. View the best growth stocks for 2023 here. When is MiMedx Group's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023. View our MDXG earnings forecast. How were MiMedx Group's earnings last quarter? MiMedx Group, Inc. (NASDAQ:MDXG) announced its quarterly earnings results on Tuesday, November, 2nd. The company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.08) by $0.04. The firm earned $63.07 million during the quarter, compared to the consensus estimate of $60.26 million. During the same period in the prior year, the business earned ($0.48) earnings per share. What ETF holds MiMedx Group's stock ? Invesco Nasdaq Future Gen 200 ETF holds 5,917 shares of MDXG stock, representing 0.64% of its portfolio. What is MiMedx Group's stock symbol? MiMedx Group trades on the NASDAQ under the ticker symbol "MDXG." Who are MiMedx Group's major shareholders? MiMedx Group's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (6.99%), Paradigm Capital Management Inc. NY (3.00%), State Street Corp (2.90%), Geode Capital Management LLC (2.01%), Richmond Brothers Inc. (1.37%) and Cannell Capital LLC (0.95%). Insiders that own company stock include Mark Graves, Peter M Carlson, Robert Benjamin Stein, Rohit Kashyap, Scott M Turner, Timothy R Wright, William Frank Iv Hulse and William Lawrence Phelan. View institutional ownership trends. How do I buy shares of MiMedx Group? Shares of MDXG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is MiMedx Group's stock price today? One share of MDXG stock can currently be purchased for approximately $7.73. How much money does MiMedx Group make? MiMedx Group (NASDAQ:MDXG) has a market capitalization of $897.53 million and generates $267.84 million in revenue each year. The company earns $-30,200,000.00 in net income (profit) each year or ($0.17) on an earnings per share basis. How many employees does MiMedx Group have? The company employs 867 workers across the globe. How can I contact MiMedx Group? MiMedx Group's mailing address is 1775 W OAK COMMONS COURT NE, MARIETTA GA, 30062. The official website for the company is www.mimedx.com. The company can be reached via phone at (770) 651-9100, via email at investorrelations@mimedx.com, or via fax at 678-384-6741. This page (NASDAQ:MDXG) was last updated on 9/21/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MiMedx Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.